MAbSilico

MAbSilico is a deep-tech company originating from a French academic research laboratory. Established in 2017, MAbSilico is a software editor. Its vision is to accelerate the development of therapeutic antibodies and focus on early-stage development. MAbSilico is developing a software suite that combines algorithms and databases, based on 20 years of proven research and protected by patents. Our artificial intelligence and machine learning-driven tools cover two key steps in early antibody development: lead identification and lead characterization. Our goal is to help customers more effectively select the best candidates and protect their IP, using only the DNA sequence of the antibody.